Taros Chemicals, a German small molecule CRO, inked a partnership deal with Spain’s Welab in an effort to broaden their scope of R&D offerings to clients.
Under the agreement, pharma and biotech companies will get access to Taros’ synthetic and medicinal chemistry expertise that covers "hit identification, hit to lead and lead optimization" as well as drug design and molecular modeling services.
Welab’s contribution is its R&D platform providing in vitro and in vivo pharmacology, drug metabolism and pharmacokinetics, and toxicology services, the two companies said in an April 12 press release. Financial terms of the deal weren’t disclosed.
Combined, the two offer a library of more than 115,000 druglike compounds and address specific modalities like peptides and oligonucleotides chemistry.
“Many of our customers have kept asking our drug discovery experts for genuine native integrated biology services,” Taros CEO Dimitrios Tzalis said in the release. “Establishing this partnership with our Spanish colleagues will now close this gap and provide our clients with an end-to-end portfolio along the execution of their pre-clinical development programs.”